600276 恒瑞医药
已收盘 11-18 15:00:00
资讯
新帖
简况
恒瑞医药11月18日主力资金流出7581万元 连续7日减仓
市场透视 · 11-18 15:18
恒瑞医药11月18日主力资金流出7581万元 连续7日减仓
概念掘金 | 司美格鲁肽减肥药正式在中国上市,多家电商平台已上线
格隆汇 · 11-17 14:35
概念掘金 | 司美格鲁肽减肥药正式在中国上市,多家电商平台已上线
多种模式并驾齐驱 创新药出海捷报频传
美港电讯 · 11-16 08:29
多种模式并驾齐驱 创新药出海捷报频传
恒瑞医药获得发明专利授权:“三嗪二酮类衍生物、其制备方法及其在医药上的应用”
证券之星 · 11-16
恒瑞医药获得发明专利授权:“三嗪二酮类衍生物、其制备方法及其在医药上的应用”
恒瑞医药11月15日遭主力抛售1.11亿元 环比减少45.23%
市场透视 · 11-15
恒瑞医药11月15日遭主力抛售1.11亿元 环比减少45.23%
恒瑞医药(600276.SH)子公司HRS-5632注射液获得药物临床试验批准通知书
智通财经 · 11-14
恒瑞医药(600276.SH)子公司HRS-5632注射液获得药物临床试验批准通知书
恒瑞医药最新公告:子公司获SHR-2173注射液药物临床试验批准通知书
证券之星 · 11-14
恒瑞医药最新公告:子公司获SHR-2173注射液药物临床试验批准通知书
恒瑞医药最新公告:子公司获得HRS-5632注射液药物临床试验批准通知书
证券之星 · 11-14
恒瑞医药最新公告:子公司获得HRS-5632注射液药物临床试验批准通知书
恒瑞医药11月14日遭主力大幅抛售2.03亿元 环比增加497.53%
市场透视 · 11-14
恒瑞医药11月14日遭主力大幅抛售2.03亿元 环比增加497.53%
中国股市:沪综指早盘近收平医药股领跌,野村上调中国第四季经济增速预测
路透中文 · 11-13
中国股市:沪综指早盘近收平医药股领跌,野村上调中国第四季经济增速预测
香港IPO活动开始回升 银行家预计亚洲发行交易“饥荒”将会缓解
美港电讯 · 11-12
香港IPO活动开始回升 银行家预计亚洲发行交易“饥荒”将会缓解
恒瑞医药11月11日主力净流出6607万元 散户资金买入
市场透视 · 11-11
恒瑞医药11月11日主力净流出6607万元 散户资金买入
恒瑞医药(600276.SH):7款药物获得药物临床试验批准通
智通财经 · 11-08
恒瑞医药(600276.SH):7款药物获得药物临床试验批准通
恒瑞医药最新公告:获得药物临床试验批准通知书
证券之星 · 11-08
恒瑞医药最新公告:获得药物临床试验批准通知书
恒瑞医药11月08日主力净流出9371万元 散户资金买入
市场透视 · 11-08
恒瑞医药11月08日主力净流出9371万元 散户资金买入
医药行业专题报告:24Q3医药持仓维持低位 恒瑞医药持仓攀升
长城证券股份有... · 11-08
医药行业专题报告:24Q3医药持仓维持低位 恒瑞医药持仓攀升
恒瑞医药,拟赴香港上市,保荐人可能包括花旗、摩根士丹利
瑞恩资本Ryanbe... · 11-08
恒瑞医药,拟赴香港上市,保荐人可能包括花旗、摩根士丹利
新股消息 | 传恒瑞医药(600276.SH)选定花旗、大摩牵头统筹香港IPO
智通财经 · 11-07
新股消息 | 传恒瑞医药(600276.SH)选定花旗、大摩牵头统筹香港IPO
恒瑞医药11月07日获主力大幅加仓1.89亿元 环比增加1817.70%
市场透视 · 11-07
恒瑞医药11月07日获主力大幅加仓1.89亿元 环比增加1817.70%
患者死亡风险降低!恒瑞医药(600276.SH)公布伊立替康脂质体最新临床数据
智通财经 · 11-07
患者死亡风险降低!恒瑞医药(600276.SH)公布伊立替康脂质体最新临床数据
加载更多
公司概况
公司名称:
江苏恒瑞医药股份有限公司
所属行业:
医药制造业
上市日期:
2000-10-18
主营业务:
江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司严格遵守环境保护法,依法持证排污,并按时缴纳环境保护税,环保信用评价等级为“绿色”,为“环保示范性企事业单位”及江苏省“绿色发展领军企业”,获得连云港经济技术开发区企业“环境保护质量奖”荣誉。
发行价格:
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":47.2,"timestamp":1731913200000,"preClose":47.7,"halted":0,"volume":30353555,"delay":0,"floatShares":6379000000,"shares":6379000000,"eps":0.8541,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.5,"latestTime":"11-18 15:00:00","open":47.71,"high":48.06,"low":47,"amount":1444000000,"amplitude":0.0222,"askPrice":47.21,"askSize":119,"bidPrice":47.2,"bidSize":851,"shortable":0,"etf":0,"ttmEps":0.8541,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"adjPreClose":47.7,"symbolType":"stock","openAndCloseTimeList":[[1731893400000,1731900600000],[1731906000000,1731913200000]],"highLimit":52.47,"lowLimit":42.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"pbRate":6.88,"roa":"--","roe":"10.88%","epsLYR":0.68,"committee":0.620178,"marketValue":301089000000,"floatMarketCap":301089000000,"peRate":55.26285,"changeRate":-0.0105,"turnoverRate":0.0048,"status":1},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2484680611","title":"恒瑞医药11月18日主力资金流出7581万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2484680611","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484680611?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:18","pubTimestamp":1731914315,"startTime":"0","endTime":"0","summary":"11月18日, 恒瑞医药股价跌1.05%,报收47.20元,成交金额14.44亿元,换手率0.48%,振幅2.22%,量比0.61。恒瑞医药今日主力资金净流出7581万元,连续7日净流出,上一交易日主力净流出1.11亿元,今日环比减少31.91%。该股近5个交易日下跌4.51%,主力资金累计净流出4.54亿元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出8.42亿元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152338abcb9dea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152338abcb9dea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064131003.USD","LU0405327494.USD","BK0060","BK0196","LU2488822045.USD","BK0188","LU2148510915.USD","600276","BK0012","LU1064130708.USD","BK0183","LU0405327148.USD","LU1328615791.USD","BK0028","BK0239"],"gpt_icon":0},{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市,多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"hk","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["NVO","BK0251","BK0070","BK0012","LU0405327148.USD","01801","BK4007","BK0028","BK0183","LU1328615791.USD","BK4585","BK0060","600276","BK0113","BK0201","BK0114","LU2148510915.USD","LU0154236417.USD","688076","BK0042","LU1093756168.USD","LU1064131003.USD","002821","300003","BK0132","BK0196","LU1093756325.SGD","603456","LU0405327494.USD","IE00BKVL7J92.USD","BK0239","LU2488822045.USD","LU1064130708.USD","300199","BK0077","IE00BZ1G4Q59.USD","BK0188","BK4532","BK4588","688117"],"gpt_icon":1},{"id":"2483738558","title":"多种模式并驾齐驱 创新药出海捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2483738558","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483738558?lang=zh_cn&edition=full","pubTime":"2024-11-16 08:29","pubTimestamp":1731716986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00BN8TJ469.HKD","LU0203345920.USD","BK4550","LU0208291251.USD","LU1066053197.SGD","BK1574","LU1093756325.SGD","MRK","LU1061106388.HKD","SG9999002224.SGD","LU0265550946.USD","LU1169589451.USD","BK0196","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2106854487.HKD","LU2089984988.USD","LU2112291526.USD","161726","BK0060","159938","LU0985320562.USD","LU1169590202.USD","LU1064130708.USD","LU1989772840.SGD","09939","LU2361044865.SGD","SG9999014559.SGD","399441","SG9999014575.USD","BK1161","06978","600276","SG9999002232.USD","LU2023250504.SGD","LU0070302665.USD","BK4534","LU1057294990.SGD","LU1066051225.USD","SG9999001440.SGD","LU1983299246.USD","02162","159992","PD","BK0188","LU1291159041.SGD","BK1583","LU1917777945.USD","LU0266013472.USD"],"gpt_icon":0},{"id":"2483208582","title":"恒瑞医药获得发明专利授权:“三嗪二酮类衍生物、其制备方法及其在医药上的应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2483208582","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483208582?lang=zh_cn&edition=full","pubTime":"2024-11-16 03:46","pubTimestamp":1731699996,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示恒瑞医药新获得一项发明专利授权,专利名为“三嗪二酮类衍生物、其制备方法及其在医药上的应用”,专利申请号为CN202180065655.5,授权日为2024年11月15日。今年以来恒瑞医药新获得专利授权68个,较去年同期减少了74.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111600010538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0012","LU1064131003.USD","BK1574","600276","LU1064130708.USD","LU0405327148.USD","LU2148510915.USD","159938","09939","LU2488822045.USD","BK0188","LU1328615791.USD","BK0239","LU0405327494.USD","BK1161","BK1515","BK0196","BK0028","BK0060"],"gpt_icon":0},{"id":"2483312706","title":"恒瑞医药11月15日遭主力抛售1.11亿元 环比减少45.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483312706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483312706?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:19","pubTimestamp":1731655188,"startTime":"0","endTime":"0","summary":"11月15日, 恒瑞医药股价跌1.55%,报收47.70元,成交金额15.93亿元,换手率0.52%,振幅2.06%,量比0.59。恒瑞医药今日主力资金净流出1.11亿元,连续6日净流出,上一交易日主力净流出2.03亿元,今日环比减少45.23%。该股近5个交易日下跌3.64%,主力资金累计净流出4.45亿元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出9.45亿元,其中净流出天数为15日。净流出前三个股分别为恒瑞医药、兴齐眼药、双成药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115152949a23a1f6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115152949a23a1f6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","LU0405327148.USD","BK0188","BK0012","LU2488822045.USD","LU1064131003.USD","BK0196","LU1328615791.USD","LU0405327494.USD","BK0028","BK0239","BK0060","LU2148510915.USD","LU1064130708.USD","600276"],"gpt_icon":0},{"id":"2483828760","title":"恒瑞医药(600276.SH)子公司HRS-5632注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2483828760","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483828760?lang=zh_cn&edition=full","pubTime":"2024-11-14 17:14","pubTimestamp":1731575655,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-5632注射液的《药物临床试验批准通知书》,同意开展治疗脂蛋白紊乱的临床试验。HRS-5632注射液是公司自主研发的1类化学药物,临床前数据显示,HRS-5632给药后可有效改善脂蛋白紊乱,安全性良好。目前国内外暂无同类药物获批上市,截至目前,HRS-5632注射液相关项目累计已投入研发费用约为2,938万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK0012","LU0405327148.USD","LU1328615791.USD","BK1576","03347","600276","BK0239","LU2488822045.USD","BK0028","BK0188","BK1141","LU1064130708.USD","BK0060","LU1064131003.USD","LU0405327494.USD","BK0196","BK1583","BK0183"],"gpt_icon":0},{"id":"2483882851","title":"恒瑞医药最新公告:子公司获SHR-2173注射液药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2483882851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483882851?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:59","pubTimestamp":1731574795,"startTime":"0","endTime":"0","summary":"恒瑞医药公告,子公司广东恒瑞医药有限公司收到国家药监局核准签发关于SHR-2173注射液的《药物临床试验批准通知书》,将于近期开展临床试验。SHR-2173注射液是公司自主研发的治疗用生物制品,用于治疗原发免疫性血小板减少症(ITP),目前国内外尚无同类药物上市或在临床研发阶段。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400028325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU0405327494.USD","BK0028","BK0239","03347","BK1141","BK0012","600276","BK0196","BK0060","LU2148510915.USD","LU0405327148.USD","BK0183","BK1583","LU2488822045.USD","LU1064131003.USD","BK1576","LU1328615791.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2483828654","title":"恒瑞医药最新公告:子公司获得HRS-5632注射液药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2483828654","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483828654?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:59","pubTimestamp":1731574790,"startTime":"0","endTime":"0","summary":"恒瑞医药公告,子公司福建盛迪医药有限公司收到国家药监局关于HRS-5632注射液的《药物临床试验批准通知书》,将于近期开展临床试验。HRS-5632注射液是公司自主研发的1类化学药物,临床前数据显示可有效改善脂蛋白紊乱,安全性良好。目前国内外暂无同类药物获批上市,累计已投入研发费用约为2938万元。药物在获得临床试验批准通知书后,尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400028337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","LU2488822045.USD","BK1141","BK1583","03347","LU1064131003.USD","BK0028","LU0405327494.USD","LU1328615791.USD","BK0183","BK0196","BK0060","BK0239","BK0188","LU0405327148.USD","600276","LU1064130708.USD","BK1576","LU2148510915.USD"],"gpt_icon":0},{"id":"2483684573","title":"恒瑞医药11月14日遭主力大幅抛售2.03亿元 环比增加497.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483684573","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483684573?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:18","pubTimestamp":1731568731,"startTime":"0","endTime":"0","summary":"11月14日, 恒瑞医药股价跌1.82%,报收48.45元,成交金额19.12亿元,换手率0.61%,振幅2.57%,量比0.65。恒瑞医药今日主力资金净流出2.03亿元,连续5日净流出,上一交易日主力净流出3402万元,今日环比增加497.53%。该股近5个交易日下跌3.10%,主力资金累计净流出4.27亿元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出7.71亿元,其中净流出天数为14日。净流出前三个股分别为恒瑞医药、科伦药业、兴齐眼药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114152541a23681dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114152541a23681dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","LU0405327148.USD","BK0188","BK0012","LU2488822045.USD","LU1064131003.USD","BK0196","LU1328615791.USD","LU0405327494.USD","BK0028","BK0239","BK0060","LU2148510915.USD","LU1064130708.USD","600276"],"gpt_icon":0},{"id":"2483501420","title":"中国股市:沪综指早盘近收平医药股领跌,野村上调中国第四季经济增速预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2483501420","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483501420?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:44","pubTimestamp":1731469444,"startTime":"0","endTime":"0","summary":"路透上海11月13日 - 中国股市沪综指周三早盘近持平收盘,在上日大跌后稍有企稳,医药板块领跌。日本投行野村上调中国第四季经济增速预测。投行野村周三称,在依然不明朗的情况下,上调中国第四季国内生产总值按年增长预测至4.9%,原为4.4%。报导称美国要求台积电停止向中国供应AI应用芯片,中国国台办周三回应称,有关报道再次证明,美国打“台湾牌”升高台海紧张局势,目的是“以台遏华”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4S3MK0BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1064131003.USD","BK0060","600276","LU1064130708.USD","LU2488822045.USD","BK0012","LU0405327148.USD","BK0188","BK0028","BK0183","BK0196","LU1328615791.USD","LU2148510915.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2482279123","title":"香港IPO活动开始回升 银行家预计亚洲发行交易“饥荒”将会缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=2482279123","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482279123?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:11","pubTimestamp":1731373867,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["603288","BK0012","IE00BYTNYN87.SGD","LU2148510915.USD","BK0183","LU0405327494.USD","BK0060","LU2580892789.USD","LU1328615791.USD","LU1064131003.USD","MCHmain","LU2580892862.HKD","02833","IE00B12V2V27.USD","LU1242518857.USD","002352","BK0187","MHImain","BK0188","BK0226","LU1064130708.USD","LU2488822045.USD","BK0197","LU0979878070.USD","HSI","IE00BYQNZ168.SGD","BK0175","513600","BK0196","BK0232","LU1242518931.SGD","HHImain","BK0028","BK0239","LU0405327148.USD","HSImain","600276"],"gpt_icon":0},{"id":"2482278929","title":"恒瑞医药11月11日主力净流出6607万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2482278929","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482278929?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:18","pubTimestamp":1731309531,"startTime":"0","endTime":"0","summary":"11月11日, 恒瑞医药股价跌0.14%,报收49.43元,成交金额28.70亿元,换手率0.92%,振幅2.77%,量比1.09。恒瑞医药今日主力资金净流出6607万元,上一交易日主力净流出9371万元,今日环比减少29.50%。该股近5个交易日上涨3.00%,主力资金累计净流入3325万元;近20日主力资金累计净流出5.37亿元,其中净流出天数为12日。净流出前三个股分别为恒瑞医药、华东医药、复星医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152233a22bb043&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152233a22bb043&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","LU2148510915.USD","LU1328615791.USD","BK0060","LU2488822045.USD","LU1064131003.USD","BK0028","600276","BK0196","BK0239","BK0188","LU0405327148.USD","LU1064130708.USD","LU0405327494.USD","BK0183"],"gpt_icon":0},{"id":"2481123195","title":"恒瑞医药(600276.SH):7款药物获得药物临床试验批准通","url":"https://stock-news.laohu8.com/highlight/detail?id=2481123195","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481123195?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:33","pubTimestamp":1731058430,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药 发布公告,近日,公司及子公司山东盛迪医药有限公司、成都盛迪医药有限公司、上海盛迪医药有限公司和苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于HRS-2189片、HRS-5041片、HRS-1358片、HRS-8080片、SHR-8068注射液、阿得贝利单抗注射液和HRS-6209胶囊的《药物临床试验批准通知书》,将于近期开展临床试验。国内外尚无同类药物获批上市。截至目前,阿得贝利单抗注射液相关项目累计已投入研发费用约6.89亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0060","LU0405327494.USD","LU0405327148.USD","BK1576","BK0239","BK1141","03347","BK0196","LU1328615791.USD","BK0012","LU2488822045.USD","LU1064131003.USD","BK0188","BK0183","LU2148510915.USD","LU1064130708.USD","600276","BK0028"],"gpt_icon":0},{"id":"2481140463","title":"恒瑞医药最新公告:获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481140463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481140463?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:10","pubTimestamp":1731057041,"startTime":"0","endTime":"0","summary":"恒瑞医药公告,公司及子公司收到国家药监局核准签发关于HRS-2189片、HRS-5041片、HRS-1358片、HRS-8080片、SHR-8068注射液、阿得贝利单抗注射液和HRS-6209胶囊的《药物临床试验批准通知书》,将于近期开展临床试验。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800028155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","03347","LU1328615791.USD","LU2488822045.USD","LU1064131003.USD","LU1064130708.USD","BK0239","LU2148510915.USD","BK0188","BK1576","BK1583","LU0405327148.USD","600276","BK0028","BK0012","BK1141","BK0183","LU0405327494.USD","BK0060"],"gpt_icon":0},{"id":"2481148516","title":"恒瑞医药11月08日主力净流出9371万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2481148516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481148516?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:17","pubTimestamp":1731050250,"startTime":"0","endTime":"0","summary":"11月08日, 恒瑞医药股价跌1.00%,报收49.50元,成交金额32.41亿元,换手率1.02%,振幅2.70%,量比1.22。恒瑞医药今日主力资金净流出9371万元,上一交易日主力净流入1.89亿元。该股近5个交易日上涨4.08%,主力资金累计净流入1.94亿元;近20日主力资金累计净流出4.62亿元,其中净流出天数为11日。净流出前三个股分别为复星医药、恒瑞医药、科伦药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108152145a2232d53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108152145a2232d53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","LU2148510915.USD","BK0239","BK0028","BK0060","BK0183","LU0405327148.USD","LU1328615791.USD","BK0196","LU0405327494.USD","LU1064130708.USD","BK0188","LU2488822045.USD","BK0012","LU1064131003.USD"],"gpt_icon":0},{"id":"2481119809","title":"医药行业专题报告:24Q3医药持仓维持低位 恒瑞医药持仓攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2481119809","media":"长城证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481119809?lang=zh_cn&edition=full","pubTime":"2024-11-08 13:51","pubTimestamp":1731045094,"startTime":"0","endTime":"0","summary":"年初至今医药板块持续承压。2024 年1 月1 日至2024 年10 月31 日,申万医药指数下跌11.19%,跑输沪深300 指数24.60 个百分点。在申万31 个一级行业中,医药行业涨跌幅位列第31 名。恒生医疗保健指数下跌13.66%,跑输恒生指数34.68 个百分点。2024Q3 医药行业基金持仓比例10.18%,环比减少0.61 个百分点。个股方面, 2024Q3 医药行业基金持股比例排名前十的个股分别是恒瑞医药、迈瑞医疗、药明康德、爱尔眼科、泰格医药、联影医疗、惠泰医疗、科伦药业、康龙化成、片仔癀。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108135137a222de8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108135137a222de8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","LU0405327148.USD","159938","BK0188","BK0012","LU2488822045.USD","LU1064131003.USD","BK0196","LU1328615791.USD","LU0405327494.USD","BK0028","BK0239","BK0060","LU2148510915.USD","LU1064130708.USD","600276"],"gpt_icon":0},{"id":"2481811532","title":"恒瑞医药,拟赴香港上市,保荐人可能包括花旗、摩根士丹利","url":"https://stock-news.laohu8.com/highlight/detail?id=2481811532","media":"瑞恩资本Ryanbe...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481811532?lang=zh_cn&edition=full","pubTime":"2024-11-08 13:20","pubTimestamp":1731043200,"startTime":"0","endTime":"0","summary":"外媒最新消息指,来自江苏连云港的内地医药巨头恒瑞医药,正在准备于2025年赴香港IPO募资,选定花旗、摩根士丹利牵头统筹香港IPO,并拟募资约20亿美元。恒瑞医药曾在10月中传出有意香港IPO集资。恒瑞医药当时在上交所发公告,承认正研究境外融资,正处于前期工作,具体实施方式以及实施时间具有重大不确定性。截至午间收市,恒瑞医药每股报人民币48.51元,总市值约人民币3094.45亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0405327148.USD","LU0267386448.USD","BK0028","BK0060","LU2236285917.USD","LU1074936037.SGD","IE00BKVL7J92.USD","LU0106831901.USD","LU0098860793.USD","BK4585","LU1363072403.SGD","BK4581","BK4588","BK4127","LU2148510915.USD","LU0006306889.USD","LU0128525689.USD","BK0239","LU2488822045.USD","LU0162691827.USD","BK0183","LU2456880835.USD","LU0320765646.SGD","LU0980610538.SGD","BK4566","IE00BZ1G4Q59.USD","LU0310800965.SGD","LU0072461881.USD","LU1989772840.SGD","BK4516","LU1366192091.USD","BK0196","LU1328615791.USD","BK0012","LU1162221912.USD","LU2357305700.SGD","LU0106261372.USD","LU0971096721.USD","BK4207","LU0405327494.USD","LU1064130708.USD","LU1064131003.USD","LU1720051017.SGD","LU0225283273.USD","LU1201861249.SGD","BK4504","LU0648001328.SGD","LU2417539215.USD","600276","LU0477156953.USD"],"gpt_icon":0},{"id":"2481693971","title":"新股消息 | 传恒瑞医药(600276.SH)选定花旗、大摩牵头统筹香港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2481693971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481693971?lang=zh_cn&edition=full","pubTime":"2024-11-07 18:56","pubTimestamp":1730976995,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,A股医药龙头恒瑞医药正筹备2025年香港IPO集资,有报道指,恒瑞医药选定花旗、大摩牵头统筹香港IPO,并拟集资约20亿美元。恒瑞医药10月中传出有意香港IPO集资。10月24日晚,恒瑞医药公布2024年三季度业绩报告,前三季度恒瑞医药实现营业收入201.89亿元,同比增18.67%,归属于上市公司股东的净利润46.20亿元,同比增32.98%,归属于上市公司股东的扣除非经常性损益的净利润46.16亿元,同比增37.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4566","LU2456880835.USD","LU0106831901.USD","LU1548497426.USD","BK0183","BK0060","LU2236285917.USD","600276","LU2357305700.SGD","IE00BKVL7J92.USD","BK4585","IE00BSNM7G36.USD","LU0310800965.SGD","LU0225283273.USD","LU0971096721.USD","LU0130517989.USD","LU1162221912.USD","LU0405327494.USD","BK4588","LU0006306889.USD","LU1267930227.SGD","LU1668664300.SGD","LU1363072403.SGD","BK4581","LU0648001328.SGD","LU1064131003.USD","LU1720051108.HKD","LU2148510915.USD","LU0267386448.USD","LU0477156953.USD","BK0012","BK0239","LU0106261372.USD","LU1328615791.USD","LU2488822045.USD","LU1074936037.SGD","BK0188","BK4207","BK4504","IE00BZ1G4Q59.USD","LU0072461881.USD","LU0130102774.USD","LU2417539215.USD","LU1720051017.SGD","BK4534","LU1366192091.USD","LU1201861249.SGD","LU1064130708.USD","LU0128525689.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2481947463","title":"恒瑞医药11月07日获主力大幅加仓1.89亿元 环比增加1817.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481947463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481947463?lang=zh_cn&edition=full","pubTime":"2024-11-07 15:17","pubTimestamp":1730963845,"startTime":"0","endTime":"0","summary":"11月07日, 恒瑞医药股价涨2.56%,报收50.00元,成交金额28.83亿元,换手率0.92%,振幅3.26%,量比1.15。恒瑞医药今日主力资金净流入1.89亿元,上一交易日主力净流入983万元,今日环比增加1817.70%。该股近5个交易日上涨7.30%,主力资金累计净流入5.18亿元;近20日主力资金累计净流出3.88亿元,其中净流出天数为11日。该行业中净流入前三个股分别为恒瑞医药、誉衡药业、新华制药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107151952aba909f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107151952aba909f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","LU1064131003.USD","BK0183","BK0188","LU0405327148.USD","600276","LU0405327494.USD","BK0060","LU1328615791.USD","LU2148510915.USD","BK0012","BK0239","LU1064130708.USD","BK0028","LU2488822045.USD"],"gpt_icon":0},{"id":"2481902299","title":"患者死亡风险降低!恒瑞医药(600276.SH)公布伊立替康脂质体最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902299","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481902299?lang=zh_cn&edition=full","pubTime":"2024-11-07 10:31","pubTimestamp":1730946671,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,11月6日,恒瑞医药宣布,一项伊立替康脂质体(Ⅱ)联合5-FU/LV二线治疗经吉西他滨治疗失败后局部晚期或转移性胰腺癌的随机、双盲、平行对照、多中心3临床研究全文发表于《自然》杂志子刊《信号转导与靶向治疗》。研究结果表明,伊立替康脂质体(Ⅱ)联合方案相较于对照组,胰腺癌患者死亡风险降低了37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600276","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","BK0239","BK0060","BK0028","LU1064130708.USD","LU2148510915.USD","BK0196","LU0405327494.USD","BK0012","LU2488822045.USD","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0451},{"period":"1month","weight":-0.065},{"period":"3month","weight":0.1172},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.0063},{"period":"ytd","weight":0.0488}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"15265股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":" 江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司严格遵守环境保护法,依法持证排污,并按时缴纳环境保护税,环保信用评价等级为“绿色”,为“环保示范性企事业单位”及江苏省“绿色发展领军企业”,获得连云港经济技术开发区企业“环境保护质量奖”荣誉。","serverTime":1731973625050,"listedPrice":11.98,"stockholders":"417865人(较上一季度减少8.23%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}